Xilio Therapeutics, Inc. (XLO) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
XLO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
XLO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -95.9% | 0.0% |
| 2024 | 100.0% | -954.9% | -918.0% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export XLO earnings history in CSV or JSON format
Free sign-in required to download data
Xilio Therapeutics, Inc. (XLO) Earnings Overview
As of May 8, 2026, Xilio Therapeutics, Inc. (XLO) reported trailing twelve-month net income of $0, reflecting +72.5% year-over-year growth. The company earned $-4.19 per diluted share over the past four quarters.
Looking at the long-term picture, XLO's historical earnings data spans multiple years. The company achieved its highest annual net income of $0 in fiscal 2025, representing a new all-time high.
Xilio Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTX (-$103M net income), IMVT (-$464M net income), RCUS (-$369M net income, -142.9% margin), XLO has comparable earnings metrics. Compare XLO vs NKTX →
XLO Earnings vs Peers
Earnings metrics vs comparable public companies
XLO Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | +100.0% | -$42M | $-4.19 | 0.0% | -95.9% |
| 2024 | -$58M | +23.8% | -$61M | $-15.26 | -918.0% | -954.9% |
| 2023 | -$76M | +13.4% | -$79M | $-38.92 | - | - |
| 2022 | -$88M | -16.4% | -$89M | $-45.08 | - | - |
| 2021 | -$76M | -37.3% | -$75M | $-189.28 | - | - |
| 2020 | -$55M | -219.0% | -$55M | $-1475.88 | - | - |
| 2019 | -$17M | - | -$19M | $-592.06 | - | - |
See XLO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XLO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XLO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXLO — Frequently Asked Questions
Quick answers to the most common questions about buying XLO stock.
Is XLO growing earnings?
XLO EPS is $-4.19, with earnings growth accelerating to +72.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $0.00.
What are XLO's profit margins?
Xilio Therapeutics, Inc. net margin is N/A, with operating margin at -95.9%. Below-average margins reflect competitive or cost pressures.
How consistent are XLO's earnings?
XLO earnings data spans 2019-2025. The accelerating earnings trend is +72.5% YoY. Historical data enables comparison across business cycles.